Humanoid Robotics Deployment Audit 2026

Humanoid robot deployment status at Apptronik, Figure, 1X, and Tesla in 2026

At the start of 2024, the standard framing for humanoid robots was speculative: impressive demos, venture capital conviction, and timelines anchored to optimistic projections rather than production data. Two years later, that framing has shifted just enough to matter — and not nearly enough to validate the hype. Several companies have moved units into customer … Read more

Synchron BCI Pivotal Trial: Endpoint and Reimbursement Path

Brain-computer interface signal path leading to a reimbursement icon, representing how Synchron's pivotal trial endpoint choice determines BCI reimbursement.

Synchron’s $200 million Series D, closed November 6, 2025, committed the company to one specific deliverable: a pivotal trial in 2026. The company has navigated a decade of neuroengineering to get here — the endovascular Stentrode approach, the SWITCH and COMMAND feasibility studies, FDA IDE approval, Apple HID integration, and a Cognitive AI division. What … Read more

CAR-T for Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem

CAR-T solid tumors trial readouts illustration showing 2026 clinical pipeline progress

CAR-T Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem — For more than a decade, CAR-T cell therapy has been one of oncology’s most electrifying stories — and one of its most stubbornly partial ones. The technology can cure relapsed blood cancers that once carried months-long prognoses. It is less effective against the … Read more